RNS Number : 6893G
Eurocell plc
27 November 2020
27 November 2020
Eurocell plc
Director/PDMR Shareholding
Eurocell plc (the "Company") announces that, on 25 November 2020:
·
options granted on 4 April 2017 under
the Eurocell plc Deferred Share Plan 2015, to acquire ordinary shares in the Company,
were exercised by
2 directors; and
·
shares acquired, as a result of the above exercise, were sold by 2 directors to cover the associated tax and national insurance liabilities
The notifications set out below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
|
1.
|
Details of PDMR / person closely associated with them ("PCA")
|
|
a)
|
Name
|
A - Mark Kelly
B - Michael Scott
|
|
2.
|
Reason for the notification
|
|
a)
|
Position / status
|
A - Chief Executive Officer
B - Chief Financial Officer
|
|
b)
|
Initial notification / amendment
|
Initial Notification
|
|
3.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Eurocell plc
|
|
b)
|
Legal Entity Identifier
|
213800RH62IQ7S9OFQ55
|
|
4.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of £0.001 each in the Company ("Ordinary Shares")
ISIN Number GB00BVV2KN49
|
|
b)
|
Nature of the transaction
|
Exercise of nil-cost options to acquire ordinary shares under the Eurocell plc Deferred Share Plan 2015
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
A - £nil (option price)
B - £nil (option price)
|
A - 51,049
B - 14,273
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Aggregated price
- Aggregated total
|
N/A - single transactions
|
|
e)
|
Date of the transaction
|
25 November 2020
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
1.
|
Details of PDMR / person closely associated with them ("PCA")
|
|
a)
|
Name
|
A - Mark Kelly
B - Michael Scott
|
|
2.
|
Reason for the notification
|
|
a)
|
Position / status
|
A - Chief Executive Officer
B - Chief Financial Officer
|
|
b)
|
Initial notification / amendment
|
Initial Notification
|
|
3.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Eurocell plc
|
|
b)
|
Legal Entity Identifier
|
213800RH62IQ7S9OFQ55
|
|
4.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of £0.001 each in the Company ("Ordinary Shares")
ISIN Number GB00BVV2KN49
|
|
b)
|
Nature of the transaction
|
Sale of ordinary shares, acquired under the Eurocell plc Deferred Share Plan 2015, to cover the associated tax and national insurance liabilities
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
A - £2.125
B - £2.125
|
A - 24,115
B - 6,743
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Aggregated price
- Aggregated total
|
N/A - single transactions
|
|
e)
|
Date of the transaction
|
25 November 2020
|
|
f)
|
Place of the transaction
|
London Stock Exchange, Main Market (XLON)
|
For further information:
Eurocell plc 01773 842 100
Paul Walker
Group Company Secretary
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END
DSHPPGQWGUPUGMQ
|
